RU2017112048A3 - - Google Patents

Download PDF

Info

Publication number
RU2017112048A3
RU2017112048A3 RU2017112048A RU2017112048A RU2017112048A3 RU 2017112048 A3 RU2017112048 A3 RU 2017112048A3 RU 2017112048 A RU2017112048 A RU 2017112048A RU 2017112048 A RU2017112048 A RU 2017112048A RU 2017112048 A3 RU2017112048 A3 RU 2017112048A3
Authority
RU
Russia
Application number
RU2017112048A
Other languages
Russian (ru)
Other versions
RU2017112048A (ru
RU2717570C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017112048A publication Critical patent/RU2017112048A/ru
Publication of RU2017112048A3 publication Critical patent/RU2017112048A3/ru
Application granted granted Critical
Publication of RU2717570C2 publication Critical patent/RU2717570C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4021-aryl substituted, e.g. piretanide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2017112048A 2014-10-10 2015-09-29 Синергистические комбинации ауристана RU2717570C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462062192P 2014-10-10 2014-10-10
US62/062,192 2014-10-10
PCT/IB2015/057457 WO2016055907A1 (en) 2014-10-10 2015-09-29 Synergistic auristatin combinations

Publications (3)

Publication Number Publication Date
RU2017112048A RU2017112048A (ru) 2018-11-15
RU2017112048A3 true RU2017112048A3 (US07585860-20090908-C00112.png) 2019-05-07
RU2717570C2 RU2717570C2 (ru) 2020-03-24

Family

ID=54288858

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017112048A RU2717570C2 (ru) 2014-10-10 2015-09-29 Синергистические комбинации ауристана

Country Status (12)

Country Link
US (1) US10617670B2 (US07585860-20090908-C00112.png)
EP (2) EP3549583A1 (US07585860-20090908-C00112.png)
JP (1) JP6784668B2 (US07585860-20090908-C00112.png)
KR (1) KR20170058432A (US07585860-20090908-C00112.png)
CN (1) CN107106685A (US07585860-20090908-C00112.png)
AU (1) AU2015329625B2 (US07585860-20090908-C00112.png)
BR (1) BR112017006113A8 (US07585860-20090908-C00112.png)
CA (1) CA2907878A1 (US07585860-20090908-C00112.png)
IL (1) IL251619B (US07585860-20090908-C00112.png)
MX (1) MX2017004580A (US07585860-20090908-C00112.png)
RU (1) RU2717570C2 (US07585860-20090908-C00112.png)
WO (1) WO2016055907A1 (US07585860-20090908-C00112.png)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9765220B2 (en) 2013-08-22 2017-09-19 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
RU2762328C2 (ru) 2016-04-01 2021-12-17 Сони Корпорейшн Ультраяркие димерные или полимерные красители
EP3455300A1 (en) 2016-05-11 2019-03-20 Sony Corporation Ultra bright dimeric or polymeric dyes
WO2018022925A1 (en) 2016-07-29 2018-02-01 Sony Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same
EP3691690A1 (en) * 2017-10-05 2020-08-12 Sony Corporation Programmable polymeric drugs
WO2019088176A1 (ja) * 2017-10-31 2019-05-09 国立大学法人神戸大学 抗体薬物複合体効果増強剤
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
EP4344747A3 (en) * 2017-11-30 2024-07-03 LadRx Corporation Albumin-binding prodrugs of auristatin e derivatives
CN112041680A (zh) 2018-03-19 2020-12-04 索尼公司 二价金属用于增强荧光信号的应用
US12006438B2 (en) 2018-06-27 2024-06-11 Sony Group Corporation Polymeric dyes with linker groups comprising deoxyribose
WO2021062176A2 (en) 2019-09-26 2021-04-01 Sony Corporation Polymeric tandem dyes with linker groups

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1439834A1 (en) 2001-10-30 2004-07-28 Applied Research Systems ARS Holding N.V. Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
PA8577501A1 (es) 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
NZ583292A (en) * 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
JP2009506790A (ja) 2005-09-07 2009-02-19 メディミューン,エルエルシー 毒素とコンジュゲートしたeph受容体抗体
WO2008002578A2 (en) 2006-06-26 2008-01-03 Nielsen Media Research, Inc. Methods and apparatus for improving data warehouse performance
SI2074122T1 (sl) 2006-09-15 2011-10-28 Pfizer Prod Inc Pirido (2,3-d)pirimidinonske spojine in njihova uporaba kot zaviralci PI3
JP5290276B2 (ja) * 2007-05-08 2013-09-18 ジェネンテック, インコーポレイテッド システイン改変抗muc16抗体および抗体−薬物結合体
AU2008308163B2 (en) 2007-10-02 2013-03-21 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient
PT3216793T (pt) 2008-05-23 2019-05-30 Wyeth Llc Compostos de triazina como inibidores de pi3 quinase e mtor
KR101839163B1 (ko) * 2010-06-08 2018-03-15 제넨테크, 인크. 시스테인 조작된 항체 및 접합체
EP3581206A1 (en) * 2010-10-22 2019-12-18 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the p13k-akt mtor pathway
DK2694111T3 (en) 2011-04-01 2016-10-10 Wyeth Llc Antibody pharmaceutical conjugates
AR088509A1 (es) 2011-10-28 2014-06-11 Genentech Inc Combinaciones terapeuticas y metodos para tratar el melanoma
PE20141790A1 (es) * 2011-11-17 2014-11-27 Pfizer Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
DK3137114T3 (da) 2014-04-30 2021-01-25 Pfizer Anti-PTK7-antistof-lægemiddelkonjugater

Also Published As

Publication number Publication date
WO2016055907A1 (en) 2016-04-14
CA2907878A1 (en) 2016-04-10
EP3549583A1 (en) 2019-10-09
AU2015329625B2 (en) 2018-04-05
IL251619A0 (en) 2017-06-29
MX2017004580A (es) 2017-06-27
KR20170058432A (ko) 2017-05-26
CN107106685A (zh) 2017-08-29
RU2017112048A (ru) 2018-11-15
JP2017530983A (ja) 2017-10-19
BR112017006113A8 (pt) 2018-04-24
BR112017006113A2 (pt) 2017-12-19
EP3204005A1 (en) 2017-08-16
JP6784668B2 (ja) 2020-11-11
IL251619B (en) 2020-10-29
US10617670B2 (en) 2020-04-14
AU2015329625A1 (en) 2017-04-13
US20180228769A1 (en) 2018-08-16
RU2717570C2 (ru) 2020-03-24

Similar Documents

Publication Publication Date Title
BR112016016761A2 (US07585860-20090908-C00112.png)
BR112016019075A2 (US07585860-20090908-C00112.png)
BR112016017381A2 (US07585860-20090908-C00112.png)
BR112016025782A2 (US07585860-20090908-C00112.png)
BR112016025523A2 (US07585860-20090908-C00112.png)
BR112016015494A2 (US07585860-20090908-C00112.png)
AP2016009666A0 (US07585860-20090908-C00112.png)
BR112016021889A2 (US07585860-20090908-C00112.png)
BR112016020233A2 (US07585860-20090908-C00112.png)
BR112016030584A2 (US07585860-20090908-C00112.png)
BR112016023360A2 (US07585860-20090908-C00112.png)
BR112016018800A2 (US07585860-20090908-C00112.png)
RU2017112048A3 (US07585860-20090908-C00112.png)
BR112016030384A2 (US07585860-20090908-C00112.png)
BR112016022869A2 (US07585860-20090908-C00112.png)
BR112016019129A2 (US07585860-20090908-C00112.png)
BR112016015935A2 (US07585860-20090908-C00112.png)
BR112016020365A2 (US07585860-20090908-C00112.png)
BR112016018653A2 (US07585860-20090908-C00112.png)
RU2017113814A3 (US07585860-20090908-C00112.png)
BR112016001204A2 (US07585860-20090908-C00112.png)
BR122020016505A2 (US07585860-20090908-C00112.png)
BR112016017024A2 (US07585860-20090908-C00112.png)
BR112016026303A2 (US07585860-20090908-C00112.png)
BR112016021960A2 (US07585860-20090908-C00112.png)